Supplementary Online Content


eFigure. Clinical and Histologic Outcomes

This supplementary material has been provided by the authors to give readers additional information about their work.
A, Comparison of the percentage reduction in the Psoriasis Area Severity Index (PASI) at week 16 for patients who responded (responders) and did not respond (nonresponders) to treatment with adalimumab or methotrexate sodium. The bold horizontal lines in each box represent the mean; the top and bottom borders of each box, the upper and lower quartiles, respectively; and the error bars above and below, maximum and minimum values, respectively. B, Representative histologic sections for a methotrexate treatment responder, for baseline nonlesional skin (NLS), baseline lesional skin (LS), and weeks 1, 2, 4, and 16 (top, hematoxylin-eosin; bottom, keratin 16; original magnification ×10). C, Representative histologic sections for a methotrexate treatment nonresponder for NLS, LS, and weeks 1, 2, 4, and 16 (top, hematoxylin-eosin; bottom, keratin 16; original magnification ×10).